Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

N/A

2(33.3%)

Phase 4

2(33.3%)

6Total

Phase 2(2)

N/A(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06402968Recruiting

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

Role: collaborator

NCT04715373Not ApplicableCompleted

LISA in the Delivery Room for Extremely Preterm Infants

Role: collaborator

NCT05740618Phase 4Completed

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

Role: collaborator

NCT07176117Not ApplicableNot Yet Recruiting

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

Role: collaborator

NCT06007547Phase 4Recruiting

Prophylactic Minimally Invasive Surfactant Evaluation

Role: collaborator

NCT04076813Active Not Recruiting

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Role: lead

NCT06253780Completed

Multidisciplinary Study to Verify Blood Pressure Documentation and Response to Titration of Intravenous Medications

Role: collaborator

NCT04552691Unknown

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Role: collaborator

NCT03551691Phase 2Completed

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

Role: collaborator

NCT00605891Phase 2Completed

Dose Finding Study of CHF 4226 for Treating Patients With COPD

Role: collaborator

All 10 trials loaded